VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company’s capital strategy, strategic opportunities, and continued development of its proprietary BiTAC(R) technology platform and oncology pipeline.
Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing areas including corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
This appointment comes at a critical time for VERAXA as it advances its pipeline of bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company’s focus on quality-by-design principles and transformative technologies positions it to make significant strides in oncology. The addition of Willener’s expertise is likely to enhance the company’s ability to navigate the complexities of capital markets and strategic growth.
“We are thrilled to welcome Raju to VERAXA during this pivotal phase of our growth,” said Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA. “His profound experience in finance and strategic leadership will be invaluable as we continue to advance our BiTAC platform and expand our oncology pipeline. His track record of driving financial strategy and execution will help us achieve our goals.”
Willener’s appointment is part of VERAXA’s broader efforts to strengthen its leadership team and accelerate the development of its next-generation therapeutics. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
Investors and industry observers will be watching closely as VERAXA leverages Willener’s expertise to support its capital strategy and strategic opportunities. The company’s continued progress in developing antibody-based therapies for cancer could have significant implications for patients and the oncology field. For more details on the announcement, visit https://nnw.fm/jcHOU.
VERAXA’s commitment to innovation is underscored by its proprietary BiTAC(R) technology, which is designed to enhance the efficacy and safety of cancer treatments. As the company moves forward, it remains focused on delivering meaningful advancements in the fight against cancer. The latest updates on VERAXA are available in the company’s newsroom at https://ibn.fm/VRXA.
